Use of Fish Oils to Prevent Atrial Mechanical Stunning and Atrial Remodeling Due to Atrial Arrhythmia
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00232232|
Recruitment Status : Completed
First Posted : October 4, 2005
Last Update Posted : May 12, 2015
The purpose of this study is to investigate whether fish oils may be of benefit to patients with certain heart rhythm disturbances called atrial fibrillation and atrial flutter.
Atrial fibrillation and atrial flutter are two heart conditions that can be successfully treated in the hospital by an ablation (in the case of atrial flutter) or a cardioversion (in the case of atrial fibrillation). Ablation involves the application of high frequency energy waves to a particular spot in the heart. Cardioversion involves resetting the heart back to a normal rhythm with the use of an electric current.
Fish oil supplements may be of benefit to patients with heart problems. Recent evidence suggests that fish oils may benefit those with rhythm disturbances.
|Condition or disease||Intervention/treatment||Phase|
|Atrial Fibrillation Atrial Flutter||Drug: Fish oil||Phase 4|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||100 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Study Start Date :||September 2003|
|Actual Primary Completion Date :||July 2013|
|Actual Study Completion Date :||November 2013|
No Intervention: Control
No fish oil
Experimental: Fish oil
Patients prescribed 6g/day of fish oil containing 1.8g EPA+DHA in a 1.5:1 ratio
|Drug: Fish oil|
- The extent of left atrial stunning in fish oil group compared to control after reversion of atrial arrhythmias to sinus rhythm. [ Time Frame: 18 months ]
- Adverse events related to fish oil ingestion. [ Time Frame: 18 months ]Tolerability, mortality.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00232232
|Royal Melbourne Hospital|
|Melbourne, Victoria, Australia, 3050|
|Principal Investigator:||Paul Sparks||Melbourne Health|